{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:12:41Z","timestamp":1793311961454,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited evidence regarding the safety and efficacy of tenecteplase 0.25\u00a0mg\/kg in patients with acute ischemic stroke in the extended time window, either with large vessel occlusion or not. Therefore, we aim to assess its safety and efficacy for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>We searched PubMed, Scopus, and Web of Science for randomized controlled trials that compared tenecteplase 0.25\u00a0mg\/kg with the best medical management. Our primary efficacy outcomes included favorable and excellent functional outcomes, measured via the modified Rankin score (mRS), and early neurological improvements. Primary safety outcomes were mortality and symptomatic intracranial hemorrhage rates. Subgroup analyses were performed based on mRs, and the inclusion of patients eligible for mechanical thrombectomy in addition to TNK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our search found nine randomized controlled trials, of which 8 were included in the meta-analysis. A total of 3068 patients were included. Tenecteplase 0.25\u00a0mg\/kg did not differ from the control group in achieving excellent functional outcomes and favorable functional outcomes (\n                      <jats:italic>P<\/jats:italic>\n                      values: 0.15 and 0.69), while there was significant improvement in early neurological improvement (\n                      <jats:italic>P<\/jats:italic>\n                      value: 0.02). Symptomatic intracranial hemorrhage was statistically higher in the tenecteplase 0.25\u00a0mg\/kg group (\n                      <jats:italic>P<\/jats:italic>\n                      value 0.008). Subgroup analyses indicated that patients with mRS 0\u20131 who receive TNK 0.25\u00a0mg\/kg do better than those with mRS 0\u20132. Better results for TNK 0.25\u00a0mg\/kg were observed in studies that excluded patients eligible for mechanical thrombectomy in addition to TNK.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      TNK 0.25\u00a0mg\/kg appears to significantly achieve early neurological improvement with no effect in achieving excellent or favorable functional outcomes; however, it showed a significant increase in symptomatic intracranial hemorrhage. Patients who performed endovascular thrombectomy after administering TNK 0.25\u00a0mg\/kg had statistically significantly higher rates of symptomatic intracranial hemorrhage; on the other hand, current evidence endorses the use of tenecteplase 0.25\u00a0mg\/kg in patients with ischemic strokes whose baseline mRs ranges from 0 to 1. Further RCTs are necessary to validate these findings.\n                      <jats:italic>Prospero registration number<\/jats:italic>\n                      : CRD42025636473.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03466-7","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T18:24:45Z","timestamp":1764440685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of intravenous tenecteplase in patients with acute ischemic stroke in extended time window: systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1392-3505","authenticated-orcid":false,"given":"Abdelmonam M.","family":"Hagag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3491-0438","authenticated-orcid":false,"given":"Gannah S.","family":"El Labban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0927-8801","authenticated-orcid":false,"given":"Abdelrhman M.","family":"Asar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3510-9703","authenticated-orcid":false,"given":"Omar R.","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4619-4389","authenticated-orcid":false,"given":"Salma Adel","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7227-5941","authenticated-orcid":false,"given":"Mostafa A.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6387-623X","authenticated-orcid":false,"given":"Mohamed Mohsen","family":"Helal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"3466_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/17474930211065917","volume":"17","author":"VL Feigin","year":"2022","unstructured":"Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke. 2022;17:18\u201329.","journal-title":"Int J Stroke"},{"key":"3466_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","volume":"20","author":"GBD 2019 Stroke Collaborators","year":"2021","unstructured":"GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:795\u2013820.","journal-title":"Lancet Neurol"},{"key":"3466_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2024.0589","volume":"331","author":"J Kaesmacher","year":"2024","unstructured":"Kaesmacher J, Cavalcante F, Kappelhof M, Treurniet KM, Rinkel L, Liu J, et al. Time to treatment with intravenous thrombolysis before thrombectomy and functional outcomes in acute ischemic stroke: a meta-analysis. JAMA. 2024;331:764\u201377.","journal-title":"JAMA"},{"key":"3466_CR4","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2019;50:e344-418.","journal-title":"Stroke"},{"key":"3466_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","volume":"401","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401:645\u201354.","journal-title":"Lancet"},{"key":"3466_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","volume":"400","author":"BK Menon","year":"2022","unstructured":"Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161\u20139.","journal-title":"Lancet"},{"key":"3466_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209903","volume":"103","author":"L Palaiodimou","year":"2024","unstructured":"Palaiodimou L, Katsanos AH, Turc G, Asimakopoulos A-G, Mavridis D, Schellinger PD, et al. Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology. 2024;103:e209903.","journal-title":"Neurology"},{"key":"3466_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1186\/s40001-025-02983-9","volume":"30","author":"AM Hagag","year":"2025","unstructured":"Hagag AM, Kormod ME, Ads ME, El-Refaay MA, Abozaid OM, Ghanem OA, et al. Tenecteplase versus alteplase in patients with acute ischemic stroke: an updated systematic review and meta-analysis. Eur J Med Res. 2025;30:726.","journal-title":"Eur J Med Res"},{"key":"3466_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/23969873221150022","volume":"8","author":"S Alamowitch","year":"2023","unstructured":"Alamowitch S, Turc G, Palaiodimou L, Bivard A, Cameron A, De Marchis GM, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J. 2023;8:8\u201354.","journal-title":"Eur Stroke J"},{"key":"3466_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2022.344","volume":"51","author":"M Heran","year":"2024","unstructured":"Heran M, Lindsay P, Gubitz G, Yu A, Ganesh A, Lund R, et al. Canadian stroke best practice recommendations: acute stroke management, 7th edition practice guidelines update, 2022. Can J Neurol Sci. 2024;51:1\u201331.","journal-title":"Can J Neurol Sci"},{"key":"3466_CR11","unstructured":"MAGICapp-Making GRADE the Irresistible Choice-Guidelines and Evidence summaries. https:\/\/app.magicapp.org\/#\/guideline\/9272. Accessed 25 Jan 2025."},{"key":"3466_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","volume":"41","author":"P Tanswell","year":"2002","unstructured":"Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41:1229\u201345.","journal-title":"Clin Pharmacokinet"},{"key":"3466_CR13","doi-asserted-by":"crossref","unstructured":"Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716\u201322.","DOI":"10.1016\/S0140-6736(99)07403-6"},{"key":"3466_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1056\/NEJMoa1713973","volume":"378","author":"GW Albers","year":"2018","unstructured":"Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708\u201318.","journal-title":"N Engl J Med"},{"key":"3466_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1161\/STROKEAHA.124.048375","volume":"56","author":"X Cheng","year":"2025","unstructured":"Cheng X, Hong L, Lin L, Churilov L, Ling Y, Yang N, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the CHABLIS-T II randomized clinical trial. Stroke. 2025;56:344\u201354.","journal-title":"Stroke"},{"key":"3466_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","volume":"387","author":"M Goyal","year":"2016","unstructured":"Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723\u201331.","journal-title":"Lancet"},{"key":"3466_CR17","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1007\/s00415-024-12445-7","volume":"271","author":"N Wu","year":"2024","unstructured":"Wu N, Doeppner TR, Hermann DM, Gronewold J. Efficacy and safety of intravenous tenecteplase compared to alteplase before mechanical thrombectomy in acute ischemic stroke: a meta-analysis. J Neurol. 2024;271:3928\u201341.","journal-title":"J Neurol"},{"key":"3466_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","volume":"384","author":"J Emberson","year":"2014","unstructured":"Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929\u201335.","journal-title":"Lancet"},{"key":"3466_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1804355","volume":"379","author":"G Thomalla","year":"2018","unstructured":"Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611\u201322.","journal-title":"N Engl J Med"},{"key":"3466_CR20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","volume":"380","author":"H Ma","year":"2019","unstructured":"Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380:1795\u2013803.","journal-title":"N Engl J Med"},{"key":"3466_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1161\/STROKEAHA.114.008504","volume":"46","author":"SB Coutts","year":"2015","unstructured":"Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46:769\u201374.","journal-title":"Stroke"},{"key":"3466_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","volume":"366","author":"M Parsons","year":"2012","unstructured":"Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099\u2013107.","journal-title":"N Engl J Med"},{"key":"3466_CR23","doi-asserted-by":"publisher","first-page":"175628642312213","DOI":"10.1177\/17562864231221324","volume":"17","author":"L Palaiodimou","year":"2024","unstructured":"Palaiodimou L, Katsanos AH, Turc G, Romoli M, Theodorou A, Lemmens R, et al. Tenecteplase for the treatment of acute ischemic stroke in the extended time window: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2024;17:17562864231221324.","journal-title":"Ther Adv Neurol Disord"},{"key":"3466_CR24","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated August 2024). www.training.cochrane.org\/handbook: Cochrane; 2024."},{"key":"3466_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3466_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3466_CR27","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1161\/STROKEAHA.111.613273","volume":"42","author":"A Bruno","year":"2011","unstructured":"Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, et al. Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life. Stroke. 2011;42:2276\u20139.","journal-title":"Stroke"},{"key":"3466_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"W Hacke","year":"2008","unstructured":"Hacke W, Kaste M, Bluhmki E, Brozman M, D\u00e1valos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317\u201329.","journal-title":"N Engl J Med"},{"key":"3466_CR29","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","volume":"352","author":"W Hacke","year":"1998","unstructured":"Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). second European-Australasian acute stroke study investigators. Lancet. 1998;352:1245\u201351.","journal-title":"Lancet"},{"key":"3466_CR30","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1161\/STROKEAHA.111.644815","volume":"43","author":"M Mazya","year":"2012","unstructured":"Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43:1524\u201331.","journal-title":"Stroke"},{"key":"3466_CR31","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1161\/STROKEAHA.113.001972","volume":"44","author":"OO Zaidat","year":"2013","unstructured":"Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke. 2013;44:2650\u201363.","journal-title":"Stroke"},{"key":"3466_CR32","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1161\/STROKEAHA.113.001990","volume":"44","author":"AJ Yoo","year":"2013","unstructured":"Yoo AJ, Simonsen CZ, Prabhakaran S, Chaudhry ZA, Issa MA, Fugate JE, et al. Refining angiographic biomarkers of revascularization: improving outcome prediction after intra-arterial therapy. Stroke. 2013;44:2509\u201312.","journal-title":"Stroke"},{"issue":"Pt A","key":"3466_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139\u201345.","journal-title":"Contemp Clin Trials"},{"key":"3466_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5853\/jos.2023.00668","volume":"25","author":"L Wang","year":"2023","unstructured":"Wang L, Dai Y-J, Cui Y, Zhang H, Jiang C-H, Duan Y-J, et al. Intravenous tenecteplase for acute ischemic stroke within 4.5-24 hours of onset (ROSE-TNK): a phase 2, randomized, multicenter study. J Stroke. 2023;25:371\u20137.","journal-title":"J Stroke"},{"key":"3466_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(22)00484-7","volume":"22","author":"MB Roaldsen","year":"2023","unstructured":"Roaldsen MB, Eltoft A, Wilsgaard T, Christensen H, Engelter ST, Indredavik B, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2023;22:117\u201326.","journal-title":"Lancet Neurol"},{"key":"3466_CR36","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","volume":"403","author":"SB Coutts","year":"2024","unstructured":"Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. Lancet. 2024;403:2597\u2013605.","journal-title":"Lancet"},{"key":"3466_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/svn-2023-002820","volume":"9","author":"X Cheng","year":"2024","unstructured":"Cheng X, Hong L, Churilov L, Lin L, Ling Y, Zhang J, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial. Stroke Vasc Neurol. 2024;9:551\u20139.","journal-title":"Stroke Vasc Neurol"},{"key":"3466_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2402980","volume":"391","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Campbell BCV, Schwamm LH, Meng X, Jin A, Parsons MW, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med. 2024;391:203\u201312.","journal-title":"N Engl J Med"},{"key":"3466_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMoa2310392","volume":"390","author":"GW Albers","year":"2024","unstructured":"Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection. N Engl J Med. 2024;390:701\u201311.","journal-title":"N Engl J Med"},{"key":"3466_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12975-024-01231-2","volume":"16","author":"H-S Chen","year":"2024","unstructured":"Chen H-S, Chen M-R, Cui Y, Shen X-Y, Zhang H, Lu J, et al. Tenecteplase plus butyphthalide for stroke within 4.5-6 hours of onset (EXIT-BT): a phase 2 study. Transl Stroke Res. 2024;16:575\u201383.","journal-title":"Transl Stroke Res"},{"key":"3466_CR41","unstructured":"Yogendrakumar V, Campbell BCV, Churilov L, Garcia-Esperon C, Choi PMC, Cordato DJ, et al. Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial. Stroke. 2025."},{"key":"3466_CR42","first-page":"796","volume":"24","author":"Q Chang","year":"2003","unstructured":"Chang Q, Wang X-L. Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin. 2003;24:796\u2013804.","journal-title":"Acta Pharmacol Sin"},{"key":"3466_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1124\/jpet.105.098517","volume":"317","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Wang L, Li J, Wang X-L. 2-(1-hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther. 2006;317:973\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"3466_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00394","volume":"7","author":"M Bi","year":"2016","unstructured":"Bi M, Zhang M, Guo D, Bi W, Liu B, Zou Y, et al. N-butylphthalide alleviates blood-brain barrier impairment in rats exposed to carbon monoxide. Front Pharmacol. 2016;7:394.","journal-title":"Front Pharmacol"},{"key":"3466_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.5853\/jos.2018.01627","volume":"20","author":"JS Lee","year":"2018","unstructured":"Lee JS, Lee S-J, Yoo JS, Hong J-H, Kim C-H, Kim Y-W, et al. Prognosis of acute intracranial atherosclerosis-related occlusion after endovascular treatment. J Stroke. 2018;20:394\u2013403.","journal-title":"J Stroke"},{"key":"3466_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.048536","author":"A G\u00fcnkan","year":"2025","unstructured":"G\u00fcnkan A, Ferreira MY, Vilardo M, Scarcia L, Bocanegra-Becerra JE, Cardoso LJC, et al. Thrombolysis for ischemic stroke beyond the 4.5-hour window: a meta-analysis of randomized clinical trials. Stroke. 2025. https:\/\/doi.org\/10.1161\/STROKEAHA.124.048536.","journal-title":"Stroke"},{"key":"3466_CR47","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/acn3.52239","volume":"11","author":"OM Al-Janabi","year":"2024","unstructured":"Al-Janabi OM, Jazayeri SB, Toruno MA, Mahmood YM, Ghozy S, Yaghi S, et al. Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: a systematic review and meta-analysis. Ann Clin Transl Neurol. 2024;11:3310\u20139.","journal-title":"Ann Clin Transl Neurol"},{"key":"3466_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5853\/jos.2024.05715","volume":"27","author":"M Aladawi","year":"2025","unstructured":"Aladawi M, Abuawwad MT, Taha MJJ, Kozaa YA, Alrubasy WA, Hamad A, et al. Tenecteplase beyond 4.5 hours in acute ischemic stroke: a systematic review and meta-analysis of randomized clinical trials. J Stroke. 2025;27:184\u201394.","journal-title":"J Stroke"},{"key":"3466_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080489","volume":"388","author":"W Hu","year":"2025","unstructured":"Hu W, Tao C, Wang L, Chen Z, Li D, Chen W, et al. Intra-arterial tenecteplase after successful endovascular recanalisation in patients with acute posterior circulation arterial occlusion (ATTENTION-IA): multicentre randomised controlled trial. BMJ. 2025;388:e080489.","journal-title":"BMJ"},{"key":"3466_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jama.2024.23466","volume":"333","author":"J Huang","year":"2025","unstructured":"Huang J, Yang J, Liu C, Li L, Yang D, Guo C, et al. Intra-arterial tenecteplase following endovascular reperfusion for large vessel occlusion acute ischemic stroke: the POST-TNK randomized clinical trial. JAMA. 2025;333:579\u201388.","journal-title":"JAMA"},{"key":"3466_CR51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213842","volume":"105","author":"X Jiang","year":"2025","unstructured":"Jiang X, Zhao Z, Zhang Y, Luo W, Zheng K, Zhang M, et al. Intra-arterial thrombolysis following endovascular recanalization for large vessel occlusion stroke: a systematic review and meta-analysis. Neurology. 2025;105:e213842.","journal-title":"Neurology"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03466-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T02:02:43Z","timestamp":1764640963000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03466-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3466"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03466-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1203"}}